ENSG00000160201 |
U2AF1 |
acute myeloid leukemia |
missense_variant |
2.404% (129/5366) |
10 entries |
ENSG00000160201 |
U2AF1 |
myelodysplastic syndrome |
missense_variant |
7.183% (228/3174) |
20 entries |
ENSG00000160201 |
U2AF1 |
acute myeloid leukemia |
sequence_alteration |
2.404% (129/5366) |
7 entries |
ENSG00000160201 |
U2AF1 |
chronic myelomonocytic leukemia |
missense_variant |
8.775% (53/604) |
10 entries |
ENSG00000160201 |
U2AF1 |
hemangioblastoma |
sequence_alteration |
45.71% (16/35) |
1 entry |
ENSG00000160201 |
U2AF1 |
myelodysplastic syndrome |
frameshift_variant |
7.183% (228/3174) |
3 entries |
ENSG00000160201 |
U2AF1 |
myelodysplastic syndrome |
sequence_alteration |
7.183% (228/3174) |
11 entries |
ENSG00000160201 |
U2AF1 |
acute myeloid leukemia |
amino_acid_insertion |
2.404% (129/5366) |
1 entry |
ENSG00000160201 |
U2AF1 |
chronic myelomonocytic leukemia |
sequence_alteration |
8.775% (53/604) |
7 entries |
ENSG00000160201 |
U2AF1 |
lymphoid neoplasm |
sequence_alteration |
0.9967% (3/301) |
1 entry |
ENSG00000160201 |
U2AF1 |
gastric intestinal type adenocarcinoma |
missense_variant |
2.353% (2/85) |
2 entries |
ENSG00000160201 |
U2AF1 |
hairy cell leukemia |
missense_variant |
4.124% (4/97) |
2 entries |
ENSG00000160201 |
U2AF1 |
bronchoalveolar adenocarcinoma |
missense_variant |
9.091% (2/22) |
1 entry |
ENSG00000160201 |
U2AF1 |
breast ductal adenocarcinoma |
missense_variant |
0.3752% (6/1599) |
1 entry |
ENSG00000160201 |
U2AF1 |
Sinonasal Undifferentiated Carcinoma |
missense_variant |
16.67% (2/12) |
2 entries |
ENSG00000160201 |
U2AF1 |
Myelodysplastic/Myeloproliferative Neoplasm |
missense_variant |
3.03% (2/66) |
2 entries |
ENSG00000160201 |
U2AF1 |
colorectal adenocarcinoma |
sequence_alteration |
2.182% (34/1558) |
1 entry |
ENSG00000160201 |
U2AF1 |
cecum adenocarcinoma |
sequence_alteration |
2.281% (6/263) |
2 entries |
ENSG00000160201 |
U2AF1 |
colorectal adenocarcinoma |
conservative_inframe_deletion |
2.182% (34/1558) |
1 entry |
ENSG00000160201 |
U2AF1 |
Borderline Ovarian Mucinous Tumor |
missense_variant |
22.22% (2/9) |
2 entries |
ENSG00000160201 |
U2AF1 |
acute lymphoblastic leukemia |
sequence_alteration |
0.3384% (2/591) |
1 entry |
ENSG00000160201 |
U2AF1 |
thyroid carcinoma |
sequence_alteration |
0.324% (3/926) |
1 entry |
ENSG00000160201 |
U2AF1 |
esophageal squamous cell carcinoma |
missense_variant |
0.292% (2/685) |
1 entry |
ENSG00000160201 |
U2AF1 |
pancreatic ductal adenocarcinoma |
missense_variant |
1.171% (20/1708) |
3 entries |
ENSG00000160201 |
U2AF1 |
Endometrial Endometrioid Adenocarcinoma |
sequence_alteration |
1.7% (11/647) |
1 entry |
ENSG00000160201 |
U2AF1 |
skin melanoma |
missense_variant |
0.431% (5/1160) |
2 entries |
ENSG00000160201 |
U2AF1 |
bronchoalveolar adenocarcinoma |
sequence_alteration |
9.091% (2/22) |
1 entry |
ENSG00000160201 |
U2AF1 |
colorectal adenocarcinoma |
missense_variant |
2.182% (34/1558) |
2 entries |
ENSG00000160201 |
U2AF1 |
Mast Cell Neoplasm |
missense_variant |
7.895% (3/38) |
2 entries |
ENSG00000160201 |
U2AF1 |
lung adenocarcinoma |
sequence_alteration |
2.128% (54/2538) |
6 entries |
ENSG00000160201 |
U2AF1 |
bladder transitional cell carcinoma |
missense_variant |
2.397% (11/459) |
4 entries |
ENSG00000160201 |
U2AF1 |
chronic myelogenous leukemia |
missense_variant |
3.604% (4/111) |
3 entries |
ENSG00000160201 |
U2AF1 |
Ampulla of Vater Carcinoma |
missense_variant |
1.523% (3/197) |
1 entry |
ENSG00000160201 |
U2AF1 |
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
1.7% (11/647) |
1 entry |
ENSG00000160201 |
U2AF1 |
Gallbladder Adenocarcinoma |
missense_variant |
2.158% (3/139) |
2 entries |
ENSG00000160201 |
U2AF1 |
lung adenocarcinoma |
missense_variant |
2.128% (54/2538) |
7 entries |
ENSG00000160201 |
U2AF1 |
Ampulla of Vater Carcinoma |
sequence_alteration |
1.523% (3/197) |
1 entry |
ENSG00000160201 |
U2AF1 |
T-cell acute lymphoblastic leukemia |
missense_variant |
0.8876% (6/676) |
2 entries |
ENSG00000160201 |
U2AF1 |
Uterine Carcinosarcoma |
sequence_alteration |
2.703% (4/148) |
1 entry |
ENSG00000160201 |
U2AF1 |
esophageal adenocarcinoma |
sequence_alteration |
1.28% (7/547) |
1 entry |
ENSG00000160201 |
U2AF1 |
colon adenocarcinoma |
sequence_alteration |
1.595% (20/1254) |
3 entries |
ENSG00000160201 |
U2AF1 |
Gallbladder Adenocarcinoma |
sequence_alteration |
2.158% (3/139) |
1 entry |
ENSG00000160201 |
U2AF1 |
bladder transitional cell carcinoma |
sequence_alteration |
2.397% (11/459) |
4 entries |
ENSG00000160201 |
U2AF1 |
colon adenocarcinoma |
stop_gained |
1.595% (20/1254) |
1 entry |
ENSG00000160201 |
U2AF1 |
acute lymphoblastic leukemia |
missense_variant |
0.3384% (2/591) |
1 entry |
ENSG00000160201 |
U2AF1 |
cervical adenocarcinoma |
missense_variant |
50.0% (2/4) |
1 entry |
ENSG00000160201 |
U2AF1 |
chronic myelomonocytic leukemia |
amino_acid_insertion |
8.775% (53/604) |
1 entry |
ENSG00000160201 |
U2AF1 |
Mast Cell Neoplasm |
sequence_alteration |
7.895% (3/38) |
2 entries |
ENSG00000160201 |
U2AF1 |
Uterine Carcinosarcoma |
missense_variant |
2.703% (4/148) |
1 entry |
ENSG00000160201 |
U2AF1 |
gastric intestinal type adenocarcinoma |
sequence_alteration |
2.353% (2/85) |
2 entries |
ENSG00000160201 |
U2AF1 |
skin melanoma |
sequence_alteration |
0.431% (5/1160) |
2 entries |
ENSG00000160201 |
U2AF1 |
hepatocellular carcinoma |
sequence_alteration |
0.293% (3/1024) |
1 entry |
ENSG00000160201 |
U2AF1 |
prostate adenocarcinoma |
sequence_alteration |
0.3713% (9/2424) |
1 entry |
ENSG00000160201 |
U2AF1 |
hairy cell leukemia |
sequence_alteration |
4.124% (4/97) |
2 entries |
ENSG00000160201 |
U2AF1 |
pancreatic ductal adenocarcinoma |
sequence_alteration |
1.171% (20/1708) |
3 entries |
ENSG00000160201 |
U2AF1 |
rectal adenocarcinoma |
sequence_alteration |
0.9158% (5/546) |
1 entry |
ENSG00000160201 |
U2AF1 |
non-small cell lung carcinoma |
missense_variant |
0.9132% (2/219) |
1 entry |
ENSG00000160201 |
U2AF1 |
squamous cell lung carcinoma |
sequence_alteration |
0.4292% (4/932) |
1 entry |
ENSG00000160201 |
U2AF1 |
diffuse large B-cell lymphoma |
missense_variant |
0.4024% (2/497) |
2 entries |
ENSG00000160201 |
U2AF1 |
thyroid carcinoma |
missense_variant |
0.324% (3/926) |
1 entry |
ENSG00000160201 |
U2AF1 |
acute myeloid leukemia |
transcript_ablation |
2.404% (129/5366) |
1 entry |
ENSG00000160201 |
U2AF1 |
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
0.7576% (2/264) |
2 entries |
ENSG00000160201 |
U2AF1 |
cecum adenocarcinoma |
missense_variant |
2.281% (6/263) |
2 entries |
ENSG00000160201 |
U2AF1 |
prostate carcinoma |
sequence_alteration |
0.7026% (3/427) |
1 entry |
ENSG00000160201 |
U2AF1 |
colon adenocarcinoma |
missense_variant |
1.595% (20/1254) |
3 entries |
ENSG00000160201 |
U2AF1 |
squamous cell lung carcinoma |
missense_variant |
0.4292% (4/932) |
1 entry |
ENSG00000160201 |
U2AF1 |
T-cell acute lymphoblastic leukemia |
sequence_alteration |
0.8876% (6/676) |
2 entries |
ENSG00000160201 |
U2AF1 |
rectal adenocarcinoma |
missense_variant |
0.9158% (5/546) |
2 entries |
ENSG00000160201 |
U2AF1 |
colon adenocarcinoma |
conservative_inframe_deletion |
1.595% (20/1254) |
2 entries |
ENSG00000160201 |
U2AF1 |
urothelial carcinoma |
sequence_alteration |
1.163% (1/86) |
1 entry |
ENSG00000160201 |
U2AF1 |
squamous cell lung carcinoma |
stop_lost |
0.4292% (4/932) |
1 entry |
ENSG00000160201 |
U2AF1 |
prostate adenocarcinoma |
frameshift_variant |
0.3713% (9/2424) |
1 entry |
ENSG00000160201 |
U2AF1 |
Tonsillar Squamous Cell Carcinoma |
sequence_alteration |
11.11% (1/9) |
1 entry |
ENSG00000160201 |
U2AF1 |
kidney Wilms tumor |
missense_variant |
0.3125% (1/320) |
1 entry |
ENSG00000160201 |
U2AF1 |
B-cell neoplasm |
sequence_alteration |
5.556% (1/18) |
1 entry |
ENSG00000160201 |
U2AF1 |
Mixed Lobular and Ductal Breast Carcinoma |
sequence_alteration |
1.562% (1/64) |
1 entry |
ENSG00000160201 |
U2AF1 |
Tonsillar Squamous Cell Carcinoma |
missense_variant |
11.11% (1/9) |
1 entry |
ENSG00000160201 |
U2AF1 |
urothelial carcinoma |
missense_variant |
1.163% (1/86) |
1 entry |
ENSG00000160201 |
U2AF1 |
undifferentiated pleomorphic sarcoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000160201 |
U2AF1 |
lung adenocarcinoma |
stop_gained |
2.128% (54/2538) |
1 entry |
ENSG00000160201 |
U2AF1 |
desmoplastic small round cell tumor |
missense_variant |
4.545% (1/22) |
1 entry |
ENSG00000160201 |
U2AF1 |
small intestinal adenocarcinoma |
missense_variant |
4.762% (1/21) |
1 entry |
ENSG00000160201 |
U2AF1 |
colorectal adenocarcinoma |
amino_acid_insertion |
2.182% (34/1558) |
1 entry |
ENSG00000160201 |
U2AF1 |
chronic myelogenous leukemia |
sequence_alteration |
3.604% (4/111) |
1 entry |
ENSG00000160201 |
U2AF1 |
basal cell carcinoma |
missense_variant |
1.471% (1/68) |
1 entry |
ENSG00000160201 |
U2AF1 |
Intimal Sarcoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000160201 |
U2AF1 |
Chronic Eosinophilic Leukemia, Not Otherwise Specified |
sequence_alteration |
33.33% (1/3) |
1 entry |
ENSG00000160201 |
U2AF1 |
B-cell acute lymphoblastic leukemia |
missense_variant |
0.885% (1/113) |
1 entry |
ENSG00000160201 |
U2AF1 |
Mantle cell lymphoma |
sequence_alteration |
1.493% (1/67) |
1 entry |
ENSG00000160201 |
U2AF1 |
nasal cavity and paranasal sinus carcinoma |
missense_variant |
4.348% (1/23) |
1 entry |
ENSG00000160201 |
U2AF1 |
adenosquamous lung carcinoma |
sequence_alteration |
4.545% (1/22) |
1 entry |
ENSG00000160201 |
U2AF1 |
prostate carcinoma |
missense_variant |
0.7026% (3/427) |
1 entry |
ENSG00000160201 |
U2AF1 |
hepatocellular carcinoma |
missense_variant |
0.293% (3/1024) |
1 entry |
ENSG00000160201 |
U2AF1 |
Chronic Neutrophilic Leukemia |
missense_variant |
25.0% (1/4) |
1 entry |
ENSG00000160201 |
U2AF1 |
diffuse large B-cell lymphoma |
sequence_alteration |
0.4024% (2/497) |
1 entry |
ENSG00000160201 |
U2AF1 |
Mantle cell lymphoma |
missense_variant |
1.493% (1/67) |
1 entry |
ENSG00000160201 |
U2AF1 |
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
1.562% (1/64) |
1 entry |
ENSG00000160201 |
U2AF1 |
Chronic Eosinophilic Leukemia, Not Otherwise Specified |
missense_variant |
33.33% (1/3) |
1 entry |
ENSG00000160201 |
U2AF1 |
B-cell neoplasm |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000160201 |
U2AF1 |
Thymic Squamous Cell Carcinoma |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000160201 |
U2AF1 |
non-small cell lung carcinoma |
sequence_alteration |
0.9132% (2/219) |
1 entry |
ENSG00000160201 |
U2AF1 |
Merkel cell skin cancer |
sequence_alteration |
1.064% (1/94) |
1 entry |
ENSG00000160201 |
U2AF1 |
colorectal adenocarcinoma |
frameshift_variant |
2.182% (34/1558) |
1 entry |
ENSG00000160201 |
U2AF1 |
breast carcinoma |
sequence_alteration |
0.1252% (2/1598) |
1 entry |
ENSG00000160201 |
U2AF1 |
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
0.2232% (1/448) |
1 entry |
ENSG00000160201 |
U2AF1 |
Borderline Ovarian Mucinous Tumor |
sequence_alteration |
22.22% (2/9) |
1 entry |
ENSG00000160201 |
U2AF1 |
multiple myeloma |
missense_variant |
0.7634% (1/131) |
1 entry |
ENSG00000160201 |
U2AF1 |
clear cell renal carcinoma |
missense_variant |
0.06901% (1/1449) |
1 entry |
ENSG00000160201 |
U2AF1 |
B-cell acute lymphoblastic leukemia |
sequence_alteration |
0.885% (1/113) |
1 entry |
ENSG00000160201 |
U2AF1 |
colon adenocarcinoma |
frameshift_variant |
1.595% (20/1254) |
1 entry |
ENSG00000160201 |
U2AF1 |
multiple myeloma |
sequence_alteration |
0.7634% (1/131) |
1 entry |
ENSG00000160201 |
U2AF1 |
Peritoneal Mesothelioma |
missense_variant |
5.556% (1/18) |
1 entry |
ENSG00000160201 |
U2AF1 |
lymphoid neoplasm |
missense_variant |
0.9967% (3/301) |
1 entry |
ENSG00000160201 |
U2AF1 |
Merkel cell skin cancer |
missense_variant |
1.064% (1/94) |
1 entry |
ENSG00000160201 |
U2AF1 |
anaplastic astrocytoma |
missense_variant |
0.7576% (1/132) |
1 entry |